Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01769222 · ClinicalTrials.gov registry record · Phase 1
Ipilimumab and Local Radiation for Selected Solid Tumors
A Phase 1 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01769222: Clinical Trial Phase 1 study, sponsored by Stanford University.
NCT01769222 is a Phase 1 study that was terminated before completion, run by Stanford University. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01769222, a Phase 1 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This pilot phase 1-2 trial studies the side effects and best of dose ipilimumab when given together with local radiation therapy and to see how well it works in treating patients with recurrent melanoma, non-Hodgkin lymphoma, colon, or rectal cancer. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Radiation therapy uses high energy x rays to kill cancer cells. Giving monoclonal antibody therapy together with radiation therapy may be an effective treatment for melanoma, non-Hodgkin lymphoma, colon, or rectal cancer. * The phase 1 component ("safety") of this study is ipilimumab 25 mg monotherapy. * The phase 2 component ("treatment-escalation") of this study is ipilimumab 25 mg plus radiation combination therapy.
Primary Outcome
Safety as the percentage of patients in Phase 1 (ipilimumab monotherapy) of the study, who experienced dose-limiting toxicities (DLTs) or serious adverse events (SAEs), using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
Interventions
- BIOLOGICAL Ipilimumab
- RADIATION Radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2013-02 |
| Est. Completion | 2015-06 |
| Phase | Phase 1 |
Why NCT01769222 stopped before completion
NCT01769222 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT01769222 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01769222 about?
NCT01769222 is a clinical study titled "Ipilimumab and Local Radiation for Selected Solid Tumors". This pilot phase 1-2 trial studies the side effects and best of dose ipilimumab when given together with local radiation therapy and to see how well it works in treating patients with recurrent melanoma, non-Hodgkin lymphoma, colon, or rectal cancer. Monoclonal antibodies, such as ipilimumab, can bl...
What is the current status of trial NCT01769222?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2013-02. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01769222?
The interventions under investigation include: Ipilimumab (BIOLOGICAL), Radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT01769222?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01769222's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia